Sustained release of ciprofloxacin from an osteoconductive poly(DL)-lactide implant

Koort, Jyri K.; Mäkinen, Tuula; Suokas, Esa; Veiranto, Minna; Jalava, Jari; Törmälä, Pertti; Aro, Hannu T.

doi:10.1080/17453670710015111

Cited by 35 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polymer microspheres based on polyparadioxanone (PPD), polyglycolic acid (PGA), or polylactic acid (PLA) can be successfully loaded with antibiotics and further immobilized to metallic substrates [288,289,290]. Unlike PMMA cements, polymer microspheres are capable of completely releasing all antibiotics in a sustained fashion thus minimizing any local or systemic toxicity associated with high fluctuating antibiotic concentrations.…”

Section: Anti-infection Coatingsmentioning

confidence: 99%

Bioactive Coatings for Orthopaedic Implants—Recent Trends in Development of Implant Coatings

Zhang

Myers

Wallace

et al. 2014

IJMS

337

165

View full text Add to dashboard Cite

Joint replacement is a major orthopaedic procedure used to treat joint osteoarthritis. Aseptic loosening and infection are the two most significant causes of prosthetic implant failure. The ideal implant should be able to promote osteointegration, deter bacterial adhesion and minimize prosthetic infection. Recent developments in material science and cell biology have seen the development of new orthopaedic implant coatings to address these issues. Coatings consisting of bioceramics, extracellular matrix proteins, biological peptides or growth factors impart bioactivity and biocompatibility to the metallic surface of conventional orthopaedic prosthesis that promote bone ingrowth and differentiation of stem cells into osteoblasts leading to enhanced osteointegration of the implant. Furthermore, coatings such as silver, nitric oxide, antibiotics, antiseptics and antimicrobial peptides with anti-microbial properties have also been developed, which show promise in reducing bacterial adhesion and prosthetic infections. This review summarizes some of the recent developments in coatings for orthopaedic implants.

show abstract

Section: Anti-infection Coatingsmentioning

confidence: 99%

Bioactive Coatings for Orthopaedic Implants—Recent Trends in Development of Implant Coatings

Zhang

Myers

Wallace

et al. 2014

IJMS

337

165

View full text Add to dashboard Cite

show abstract

“…Several CFX delivery systems have been developed for the treatment of specific infections such as microspheres, multilamellar liposomes, hydrogels, scaffolds, implants membranes, polymer blends or nanoparticles (Aranaz et al, 2009;Budai, 2007;Cho, 2003;Chouhan & Bajpai, 2010;Dias Murbach et al, 2014;DiTizio, 1998;Koort et al, 2008;Ogawa & Plepis, 2002;Venkatasubbu, Ramasamy, Ramakrishnan, & Kumar, 2011;Verma, Bansal, Gosh, & Pandit, 2012;Wang, Dong, Du,& Kennedy, 2007).…”

Section: Introductionmentioning

confidence: 98%

Chitosan based films as supports for dual antimicrobial release

Aranaz

Harris

Navarro‐García

et al. 2016

Carbohydrate Polymers

View full text Add to dashboard Cite

“…osteomyelitis, arthritis, and osteonecrosis) [98][99][100] . Long acting injections and implants have advantages over oral or transdermal administration due to the delivery and maintenance of high tissue concentrations of antibiotics to eradicate infection and prevent relapse [101][102][103] .…”

Section: Drugs For Musculoskeletal Diseasesmentioning

confidence: 99%

Drugs for Long Acting Injections and Implants

Shen

Burgess

2011

Long Acting Injections and Implants

View full text Add to dashboard Cite

Long acting injections and implants have been developed for controlled drug delivery to improve therapeutic effects, decrease dosing frequency, and also avoid potential drug toxicity. Many pharmaceutical agents, such as biomacromolecules (e.g. peptides, proteins and gene therapeutics), drugs with poor bioavailability, and drugs for local delivery are good candidates for developing long acting injections and implants. However, not all drugs are suitable for these formulations (for example, drugs with high dose or narrow therapeutic index). IntroductionDrug formulations should deliver the API (active pharmaceutical agent) to the site of action at the correct therapeutic concentration for as long as the treatment is desired. The therapeutic and the physicochemical properties of a drug determine the preferred route of administration (oral or parenteral) as well as the most appropriate delivery systems.Due to convenience and patient acceptability, oral drug delivery is the most attractive and preferred route for administering medicines. However, some drugs cannot be tolerated via the oral route due to the acid environment and the variety of proteolytic enzymes (proteases) in the gastrointestinal tract (GIT). These conditions tend to degrade or metabolize drugs such as proteins and peptides, resulting in low bioavailability [ 1 ] . Moreover, patients who are unable to tolerate oral ingestion (e.g. patients with aspiration problems or GI disorders) require nonoral administration (e.g. parenteral administration) to receive medications and nutrition. Parenteral administration (e.g. intravenous, intramuscular, and subcutaneous) is also useful

show abstract

Sustained release of ciprofloxacin from an osteoconductive poly(DL)-lactide implant

Abstract: This type of composition of implant may fulfill the requirements of bone infection therapy, for sustained local release of the selected antibiotic over several months.

Cited by 35 publications

References 18 publications

Bioactive Coatings for Orthopaedic Implants—Recent Trends in Development of Implant Coatings

Bioactive Coatings for Orthopaedic Implants—Recent Trends in Development of Implant Coatings

Chitosan based films as supports for dual antimicrobial release

Drugs for Long Acting Injections and Implants

Contact Info

Product

Resources

About